Skip to content

Single-Ingredient Series · Evidence Review

An evidence-based review of the physiological 40:1 myo-inositol to D-chiro-inositol ratio, PCOS-related outcomes, dosing, safety, and quality.

Published: June 2026Sources: 21 verified primary referencesEvidence: Umbrella reviews · Meta-analyses · RCTs · Mechanistic · Safety · Registered trials

Executive summary

What the evidence says

Myo-inositol (MI) and D-chiro-inositol (DCI) are stereoisomeric forms of inositol that function as insulin second messengers through distinct but complementary intracellular pathways. In healthy human plasma, these two isomers coexist at an approximate ratio of 40:1 in favor of myo-inositol — a ratio regulated by an insulin-stimulated epimerase and disrupted in states of insulin resistance. Pacific Formulations' Myo-Inositol + D-Chiro-Inositol Capsules deliver 2000 mg MI and 50 mg DCI per serving, precisely replicating this 40:1 ratio. At the recommended twice-daily dose (4000 mg MI + 100 mg DCI daily), the product aligns with the dosing regimens used in the majority of published clinical research. The strongest human evidence supports improvements in hormonal and metabolic parameters in women with polycystic ovary syndrome (PCOS): an umbrella review of 13 meta-analyses found significant reductions in LH (MD −3.43 IU/L), free testosterone, and HOMA-IR (MD −1.14), alongside improvements in SHBG (MD +36.72 nmol/L) and ovulation rate (RR 2.75 vs. placebo/folic acid).5 A head-to-head RCT in 56 PCOS patients established the 40:1 MI:DCI ratio as the optimal combination for restoring ovulation — outperforming six other tested ratios in a single trial.8 Preliminary evidence supports fertility outcomes including live birth rate (RR 2.29).5 A registered pilot RCT (NCT04407754) is currently evaluating this exact formulation dose — 2000 mg MI + 50 mg DCI twice daily — for PCOS-related infertility.20 Myo-inositol is FDA GRAS-affirmed. A clinical safety review of more than 250 subjects finds the 4 g/day dose completely free of adverse effects; clinically meaningful side effects appear only at doses ≥12 g/day — three times the daily dose of this product.19 Product: Myo-Inositol (2000 mg) + D-Chiro-Inositol (50 mg) Capsules — Pacific Formulations Single-Ingredient Series.

What Is the Myo-Inositol + D-Chiro-Inositol Blend?

Inositol (C₆H₁₂O₆) is a six-carbon cyclitol sugar alcohol that exists as nine possible stereoisomers. Of these, myo-inositol (MI) is the most abundant in human biology, constituting approximately 96% of free inositol in mammalian tissues. D-chiro-inositol (DCI) is the second most physiologically significant isomer, present in smaller but functionally critical amounts that vary predictably by tissue type. Both MI and DCI are obtained from the diet — primarily from fruits, legumes, whole grains, and nuts — and synthesized endogenously from glucose. DCI is additionally produced in vivo through enzymatic conversion of MI via an insulin-stimulated epimerase, a reaction that is impaired in states of insulin resistance.1

Tissue-Specific Distribution

Each tissue maintains a characteristic MI:DCI ratio reflecting its predominant metabolic role. Myoinositol is enriched in tissues requiring rapid FSH or insulin signal transduction — notably the ovaries, brain, and heart. D-chiro-inositol is enriched in tissues primarily responsible for glycogen storage and glucose disposal, including the liver and skeletal muscle. This tissue specificity is not incidental: the two isomers mediate distinct downstream signals and are not metabolically interchangeable.1,2

The 40:1 Plasma Ratio

In healthy human plasma, MI and DCI coexist at an approximate ratio of 40:1. This ratio reflects the differential rates of isomer synthesis, the regulated pace of MI-to-DCI epimerization, and tissue-specific uptake and utilization that together establish systemic equilibrium. Disruption of this balance — particularly the relative DCI deficiency seen in insulin-resistant states — is associated with impaired insulin signaling and, in women of reproductive age, the ovulatory and metabolic dysfunction characteristic of PCOS.1,3

The SKU

Pacific Formulations' Myo-Inositol + D-Chiro-Inositol Capsules provide 2000 mg of myo-inositol and 50 mg of D-chiro-inositol per serving — a 40:1 ratio precisely matching the physiological plasma ratio. At the recommended twice-daily dose, the daily total is 4000 mg MI + 100 mg DCI, the dosing regimen used in the predominant body of published clinical research.

Mechanism of Action

Inositol Phosphoglycans as Insulin Second Messengers

Insulin binding to its receptor triggers hydrolysis of glycosylphosphatidylinositol (GPI) lipids in the plasma membrane, releasing two structurally distinct classes of inositol phosphoglycans (IPGs) into the cytoplasm: IPG-A, which contains myo-inositol, and IPG-P, which contains D-chiro-inositol. These IPGs

constitute a non-receptor insulin second-messenger cascade operating in parallel with the classical PI3K/Akt pathway.2 IPG-A inhibits protein kinase A and adenylyl cyclase, producing antilipolytic and lipogenic effects. IPG-P activates pyruvate dehydrogenase phosphatase (PDHP), promoting oxidative glucose disposal, and activates protein phosphatase 2Cα, which in turn stimulates glycogen synthase. Together, these two pathways regulate both oxidative and non-oxidative glucose metabolism and modulate insulin secretion by pancreatic β-cells.1,2

The Epimerase and Insulin Resistance

The conversion of MI to DCI is catalyzed by a specific insulin-dependent epimerase. In insulin-resistant states, epimerase activity is impaired in peripheral tissues — liver, skeletal muscle, and adipose — reducing DCI production, diminishing IPG-P signaling, and worsening glucose tolerance independent of PI3K/Akt dysfunction. Urinary MI losses are simultaneously elevated in insulin resistance and type 2 diabetes, further depleting tissue inositol pools and compounding metabolic dysfunction.1,2

Myo-Inositol as FSH and TSH Second Messenger

Beyond insulin signaling, MI serves as the precursor to inositol triphosphate (IP₃), which mediates cellular responses to follicle-stimulating hormone (FSH) in ovarian granulosa cells. FSH drives follicular development, granulosa cell proliferation, and estradiol synthesis through this IP₃ pathway. Myo-inositol also mediates TSH signaling in thyroid tissue via the same second-messenger mechanism. MI deficiency at these receptor sites therefore directly impairs hormone signal transduction, independent of insulin sensitivity status.1

The Ovarian Paradox: Why the DCI Dose Must Be Constrained

In women with PCOS, a paradox operates at the ovarian level that has direct implications for supplement formulation. Unlike peripheral insulin-resistant tissues — where epimerase activity is pathologically reduced — the ovary retains insulin sensitivity. Chronic hyperinsulinemia in PCOS therefore drives excess MI→DCI epimerization within the ovary, producing paradoxical intra-ovarian MI deficiency despite systemic sufficiency. This has been confirmed by direct measurement of follicular fluid: the MI:DCI ratio in healthy women is approximately 100:1; in PCOS patients with hyperinsulinemia, this ratio collapses to approximately 0.2:1, representing near-complete MI depletion at the site of folliculogenesis.4 The mechanistic consequence is impaired FSH signaling in granulosa cells, reduced oocyte maturation, and compromised oocyte quality. Excess intra-ovarian DCI additionally suppresses aromatase, disrupting the estradiol synthesis required for follicular development.3 This "D-chiro-inositol paradox in the ovary"3 explains two clinically replicated observations: MI supplementation improves oocyte quality, while high-dose DCI monotherapy worsens it. It directly constrains supplement design: any combined MI+DCI formulation must provide DCI at a ratio that

corrects systemic DCI deficiency in peripheral tissues without flooding the ovary with excess DCI. The 40:1 ratio — matching physiological plasma — satisfies this constraint. Ratios that increase the DCI fraction progressively erode the reproductive benefit, as confirmed in clinical data (see §3d).

Evidence Review

Hormonal Profile Support in PCOS

MODERATE

The broadest available evidence synthesis is a 2026 umbrella review incorporating 13 meta-analyses of inositol RCTs in women with PCOS. AMSTAR-2 quality ratings found 23.1% of included meta-analyses to be high quality; GRADE assessment of individual evidence items yielded 18.9% moderate, 40% low, and 41.1% very low certainty. These GRADE ratings reflect the relatively small sample sizes of individual RCTs in this field, not contradictory results — the directional findings are consistent across analyses.5 Umbrella Review (2026) — 13 meta-analyses, PCOS populations. Inositol versus placebo or folic acid: LH MD −3.43 IU/L (95% CI [−4.29, −2.56], p<0.00001; GRADE: Moderate). FSH MD −0.89 (95% CI [−1.49, −0.29], GRADE: Moderate). Free testosterone MD −0.02 nmol/L (p<0.00001). SHBG MD +36.72 nmol/L (95% CI [28.52, 44.91], p<0.00001). Androstenedione significantly reduced. Cross-subgroup analysis found MI or MI+folic acid consistently superior to DCI monotherapy for metabolic and reproductive outcomes. D-chiroinositol monotherapy was flagged for use with caution in clinical practice.5

Unfer et al. (2017) — Meta-analysis, 9 RCTs, n=496. MI alone or MI+DCI vs controls. Significant reductions in fasting insulin (SMD −1.021, 95% CI [−1.791, −0.251], p=0.009) and HOMA index (SMD −0.585, 95% CI [−1.145, −0.025], p=0.041). Trend toward testosterone reduction (SMD −0.49, p=0.099, not significant). SHBG significantly increased only in studies of ≥24 weeks' duration (SMD +0.425, p=0.026). Trial sequential analysis provided firm evidence for the insulin effect.6

Benelli et al. (2016) — RCT, n=46; MI+DCI 40:1 vs folic acid placebo, 6 months. Statistically significant reductions in LH, free testosterone, fasting insulin, and HOMA index in the treatment arm only. Significant increase in 17β-estradiol in the treatment arm. No relevant side effects recorded in either group.7

The hormonal improvements are mechanistically coherent: insulin directly amplifies ovarian theca cell androgen production via LH receptor sensitization. Correcting insulin resistance via the IPG pathway attenuates this androgenic drive without requiring direct androgen-blocking mechanisms — a physiologically grounded approach to hyperandrogenism management.

Insulin Sensitivity & Metabolic Support

MODERATE

Umbrella Review (2026) — pooled meta-analytic data, PCOS. HOMA-IR: MD −1.14 (95% CI [−1.35, −0.94], p<0.00001). Fasting insulin: MD −23.40 pmol/L (95% CI [−32.80, −14.01], p<0.00001). Triglycerides: significant reduction. Effects on most metabolic parameters were not significantly different when inositol was compared directly to metformin, consistent with inositol being an insulin sensitizer of comparable magnitude but distinct mechanism.5

GRADE-Assessed Cardiometabolic Meta-analysis (2025) — 18 RCTs, n=898. Inositol supplementation improved glycemic control, lipid profiles, and anthropometric measures across populations including PCOS, obesity/metabolic syndrome, T2DM, and NAFLD. Effects were most consistent and of greatest magnitude in the PCOS subgroup. Blood pressure improvements were observed but rated low-to-very-low certainty by GRADE. High heterogeneity across non-PCOS populations limits generalizability to metabolically healthy individuals.13

The insulin-sensitizing mechanism of inositol is distinct from metformin's primary action (hepatic gluconeogenesis inhibition via AMPK). Inositol corrects the IPG second-messenger deficiency downstream of the insulin receptor — a complementary physiological target. This distinction is clinically meaningful: in direct head-to-head meta-analysis, MI and metformin achieve comparable metabolic outcomes while inositol produces substantially fewer adverse events (RR of adverse events 0.16 for inositol vs. metformin, p<0.001).11,12

Menstrual Regularity & Ovulation Support

MODERATE

Umbrella Review (2026) — pooled reproductive outcome data. Ovulation rate: RR 2.75 (95% CI [1.71, 4.41], p<0.0001) with inositol vs. placebo/folic acid. Menstrual cycle regularity was a consistently replicated secondary outcome across included meta-analyses.5

Giordano et al. (2016) — Systematic review, 12 RCTs, PCOS populations. Three RCTs specifically examined MI+DCI at the 40:1 ratio. Across these trials, combined MI+DCI therapy reduced LH, free testosterone, HOMA, and fasting insulin while significantly increasing estradiol and SHBG. Menstrual regularization and ovulation restoration were consistently reported. No relevant side effects were recorded across 40:1 combination therapy trials.14

Prospective clinical trial (2025, NCT05767515) — n=60 PCOS patients; MI+DCI 40:1 vs metformin, 12 weeks. Both treatments significantly improved menstrual regularity (p=0.002), ovarian volume (p<0.001), HOMA-IR (p<0.001), SHBG (p=0.021), BMI, quality of life, and perceived stress scores. Metformin showed marginal advantages in insulin sensitivity in the most androgenic PCOS phenotype (A); MI+DCI may offer specific advantages for phenotypes C and D. The authors note phenotype-specific tailoring as a direction for future research.15

The Ratio Rationale — Why 40:1 Specifically

MODERATE

The mechanistic case for the 40:1 ratio (ovarian paradox, tissue-specific MI:DCI requirements) is supported by a dedicated clinical trial directly comparing seven different MI:DCI ratios in the same population. Nordio, Basciani & Camajani (2019) — Comparative RCT, n=56 PCOS patients (n=8 per ratio arm), 3 months. Seven formulations were compared: DCI alone, and MI:DCI ratios of 1:3.5, 2.5:1, 5:1, 20:1, 40:1, and 80:1 (all at 2g total inositols twice daily). Primary outcome: ovulation. Secondary outcomes: FSH, LH, SHBG, 17β-estradiol, free testosterone, basal and postprandial insulin, HOMA index, BMI, and menses. The 40:1 ratio produced the best restoration of ovulation and normalization of all secondary parameters. Formulations with progressively more DCI relative to MI showed progressively worsening reproductive outcomes. DCI alone showed no meaningful benefit. The authors concluded that DCI activity is beneficial specifically at the 40:1 ratio, with increasing DCI fraction causing loss of reproductive and metabolic benefit.8

Colazingari et al. (2013) — RCT; PCOS women undergoing IVF-ET. MI (1.1 g) + DCI (27.6 mg) combined therapy vs. DCI alone (500 mg). Only the combined MI+DCI therapy improved oocyte quality, embryo quality, and clinical pregnancy rates. DCI monotherapy did not improve any of these outcomes. The authors conclude that MI plays a critical role in ovarian function in PCOS and that combined therapy is superior to DCI alone.9

Fertility Support

PRELIMINARY

Umbrella Review (2026) — pooled data, live birth outcomes. Live birth rate: RR 2.29 (95% CI [1.07, 4.93], p=0.03) with inositol vs. placebo/folic acid. This is a statistically significant signal, but is based on a small number of contributing trials and rated low certainty by GRADE.5

Monastra et al. (2020) — Retrospective case-control, n=46 PCOS patients without insulin resistance; MI:DCI 40:1 for ≥6 months. Ovulation detected in 23/29 normal-weight patients (79.3%) vs. 5/17 overweight/obese patients (29.4%, p<0.001). Spontaneous pregnancy in 6/7 (85.7%) normal-weight patients seeking conception vs. 2/6 (33.3%) in the overweight group. MI+DCI 40:1 may represent a first-line option in normal-weight PCOS patients without insulin resistance.10

NCT04407754 — Registered pilot RCT, University of Oklahoma. n=84 (42 per arm). Design: letrozole + placebo vs. letrozole + inositol supplement. Inositol arm: myo-inositol 2000 mg + D-chiroinositol 50 mg, twice daily — precisely the dose of this SKU. Population: women with PCOS-related infertility, stratified by BMI. Primary outcome: clinical pregnancy. Status: ongoing; this trial will provide the first direct RCT data on this exact formulation dose for fertility outcomes.20

Gestational Considerations

PRELIMINARY

Corrado et al. — RCT; non-obese pregnant women at high risk for gestational diabetes mellitus (GDM). Four arms: MI alone, DCI alone, combined MI+DCI, or placebo. Glycemic control (fasting, 1-hour, and 2-hour glucose) was significantly lower across all inositol-exposed groups vs. placebo (p<0.001, 0.011, and 0.037, respectively). MI alone showed the largest relative risk reduction for GDM development (RRR=0.083 vs. placebo at 8%). Combined MI+DCI achieved RRR=0.621. Need for maternal insulin therapy was numerically lower in inositol groups (1 vs. 9 patients in control group).16

GDM data are from a preliminary pilot trial and are not sufficient for definitive GDM prevention claims. Pacific Formulations does not make gestational health claims for this product. The data are presented to contextualize the mechanistic role of inositols in glucose metabolism during pregnancy.

What the Evidence Does Not Support at This Dose

Thyroid function. Myo-inositol is a known second messenger for TSH, and multiple RCTs have demonstrated that combined MI + selenomethionine supplementation significantly reduces TSH and thyroid antibody titers in patients with Hashimoto's thyroiditis and subclinical hypothyroidism. However, all published thyroid trials co-administer selenium alongside MI — there is no controlled evidence for standalone MI effects on thyroid function at any dose. Pacific Formulations makes no thyroid claims for this product. Psychiatric conditions (anxiety, depression, OCD). Inositol at pharmacological doses of 12–18 g/day has been studied in RCTs for panic disorder, major depression, and OCD. A meta-analysis of 11 RCTs (n=312 total) found no statistically significant effects on depressive or anxiety symptoms; a marginal trend appeared in PMDD only (p=0.07).17 Critically, the psychiatric research doses are 3–4.5× the total daily dose of this product. Psychiatric applications are not supported at the 4 g/day total dose level, and no claims are made.

Dosing & Usage

Clinical Dose Range

The majority of published RCTs and meta-analyses in PCOS and metabolic contexts used 4 g of myoinositol per day, typically administered in two divided doses, with DCI co-administered at the 40:1 ratio (100 mg DCI/day). The earliest landmark DCI-only study (Nestler et al., 1999) used 1200 mg DCI alone — a formulation now recognized as providing excess DCI without sufficient MI to protect ovarian function, and no longer considered the standard of care in inositol research.

Pacific Formulations Product Dose

Each serving provides 2000 mg myo-inositol + 50 mg D-chiro-inositol (40:1 ratio). At the recommended twice-daily dose: Metric

Metric Per serving Daily (2 servings)
Myo-inositol 2,000 mg 4,000 mg
D-chiro-inositol 50 mg 100 mg
Total inositols 2,050 mg 4,100 mg
MI:DCI ratio 40:1 40:1

This daily dose of 4000 mg MI is consistent with the primary clinical evidence base. The 40:1 ratio is maintained at both the per-serving and daily level.

Evidence-Based Dosing Context

Outcome area Daily dose used in evidence Duration in evidence
Hormonal profile (PCOS) 4 g MI + 100 mg DCI/day at 40:1 3-6 months across multiple RCTs and meta-analyses
Insulin sensitivity / HOMA-IR 4 g MI/day, with or without DCI 3-12 months
Ovulation / menstrual regularity 4 g MI + 100 mg DCI/day at 40:1 3-6 months across multiple RCTs
Fertility support 4 g MI + 100 mg DCI/day at 40:1 Up to 6 months

Timing

Twice-daily dosing — one serving in the morning and one in the evening, with or without food — mirrors the administration regimens used in clinical trials. Consistent daily use for a minimum of three months is typical before hormonal and metabolic outcomes are assessed in the PCOS clinical literature; some endpoints (e.g., SHBG improvement) require ≥24 weeks to reach significance.6

Who May Benefit Most

Published clinical evidence is concentrated in women of reproductive age with PCOS, hormonal irregularity, insulin resistance, anovulatory infertility, or metabolic syndrome features. Benefit is expected to track with the degree of underlying inositol imbalance or insulin sensitivity impairment. The evidence base for the general healthy adult population — in the absence of PCOS or insulin resistance — remains limited, and benefit in this population has not been systematically established.

Safety & Tolerability

No Established Upper Tolerable Intake Level

Unlike most minerals and many vitamins, neither the NIH, EFSA, nor Health Canada has established a formal Tolerable Upper Intake Level (UL) for inositol from food or dietary supplements. EFSA has concluded that animal and human toxicological data indicate low toxicity but are insufficient to define a UL. The FDA affirmed myo-inositol as Generally Recognized As Safe (GRAS) for use as a nutrient supplement (21 CFR §184.1370).21

Adverse Event Profile

A clinical safety review of more than 250 subjects exposed to myo-inositol at doses ranging from 4 to 30 g/day in controlled trials found that only the highest doses — 12 g/day or more — produced mild gastrointestinal side effects including nausea, flatulence, and loose stools. Severity did not increase further even at 30 g/day. The clinical dose of 4 g/day (the total daily dose of this product) is described in the safety literature as completely free of adverse effects.19 Comparative safety data from direct head-to-head trials with metformin confirm the favorable tolerability profile: inositol produced adverse events at a rate 84% lower than metformin (RR=0.16; metformin adverse event rate RR=5.17 relative to inositol, p<0.001).11,12 Side effects in the metformin groups included bloating, nausea, and generalized weakness; no corresponding adverse effects were reported for inositol groups.

Concomitant Medications

Lithium and valproic acid (VPA) act in part through depletion of inositol in the central nervous system. While this raises theoretical concern that supplemental inositol could reduce drug efficacy, a pilot clinical study (n=15, 4 g/day inositols for 6 months) found no interference with pharmacological therapy in

patients taking Li or VPA — and noted improvements in thyroid and metabolic markers.18 Myo-inositol does not readily cross the blood-brain barrier at peripheral supplement doses, which limits central inositol augmentation at clinical dosing levels.

Populations Requiring Caution

No specific contraindications have been identified for MI+DCI at the 40:1 ratio at the clinical 4 g/day dose. Women who are pregnant or trying to conceive should consult a healthcare provider before beginning any supplementation. Given the reproductive mechanism of action, use by individuals outside the studied population should be guided by a qualified healthcare professional.

Quality & Sourcing

What Distinguishes High-Quality MI+DCI Supplementation

1. Analytically verified 40:1 ratio. The MI:DCI ratio must be confirmed by the manufacturer via HPLC or equivalent analytical method. A formulation that approximates the 40:1 ratio by blending inositol sources of variable stereoisomeric purity may not deliver the intended ratio consistently.

2. Stereoisomeric identity of each component. Myo-inositol and D-chiro-inositol are distinct stereoisomers with non-interchangeable functions. Certificate of Analysis (CoA) data should confirm the identity of each component by specific optical rotation or equivalent method.

3. Absence of co-mixed inorganic inositol forms. Some products label themselves as "inositol blends" while including cheaper inositol fractions that do not correspond to MI or DCI. A singleingredient capsule formulation should contain only the stated MI and DCI stereoisomers plus pharmaceutical-grade excipients.

4. Third-party testing. A CoA from an ISO 17025-accredited or NSF-certified laboratory verifying identity, potency, and absence of heavy metals and microbial contaminants.

Pacific Formulations Position

Pacific Formulations' Myo-Inositol + D-Chiro-Inositol Capsules are formulated at the verified 40:1 ratio, delivering 2000 mg MI and 50 mg DCI per serving as single stereoisomers. The capsule format eliminates the taste and dissolution variability associated with powder forms. The single-formulation, defined-ratio positioning enables users and healthcare providers to assess response to a specific, traceable inositol combination — meeting the standard demanded by practitioners who require clean, evidence-matched supplementation.

Conclusion

The myo-inositol + D-chiro-inositol combination at the 40:1 ratio is grounded in well-characterized physiology. Both isomers function as insulin second messengers through distinct but complementary

phosphoglycan pathways; their tissue-specific distribution is tightly regulated; and the intra-ovarian paradox provides a clear mechanistic rationale for why the DCI dose must be constrained relative to MI. The 40:1 ratio replicates the physiological plasma balance that has been disrupted in insulin-resistant and PCOS states. The clinical evidence base is most robust for women with PCOS or related hormonal irregularity. Moderate-certainty evidence supports improvements in LH, free testosterone, SHBG, HOMA-IR, and ovulation rate with twice-daily dosing at 4 g MI + 100 mg DCI. The 40:1 ratio specifically — over other MI:DCI combinations — is supported by a dedicated clinical trial and mechanistically consistent ancillary data. Preliminary evidence supports fertility outcomes. The inositol class consistently outperforms placebo and matches metformin in metabolic efficacy while producing substantially fewer adverse effects. Key limitations are stated plainly: evidence quality by GRADE standards is moderate to low, primarily reflecting small RCT sample sizes rather than contradictory findings. The evidence base is largely PCOSspecific; effects in the general healthy adult population remain poorly characterized. Thyroid and psychiatric applications are not supported at this dose. The NCT04407754 registered trial — using exactly this product's dose — will provide prospective fertility outcome data when complete. Pacific Formulations presents this document as a working summary of the current scientific evidence — subject to update as research develops — rather than a promotional instrument.

References

Sources

  1. de Munter JS, Vogelaar IP, Kawaguchi R, et al. Inositols in Insulin Signaling and Glucose Metabolism. J Diabetes Res. 2018;2018:1968450. doi:10.1155/2018/1968450.
  2. Larner J, Brautigan DL, Thorner MO. D-Chiro-Inositol Glycans in Insulin Signaling and Insulin Resistance. Mol Med. 2010;16(11-12):543–552. doi:10.2119/molmed.2010.00107. PMC2972396.
  3. Carlomagno G, Unfer V, Roseff S. The D-chiro-inositol paradox in the ovary. Fertil Steril. 2011;95(8):2515–2516. PMID:21641593.
  4. Bizzarri M, Carlomagno G, Benvenga S, Unfer V. Hyperinsulinemia Alters Myoinositol to D-chiroinositol Ratio in the Follicular Fluid of Patients With PCOS. Reprod Sci. 2014;21(7):854–858. doi:10.1177/1933719113518985.
  5. [Authors TBD]. Effects of inositol in women with polycystic ovary syndrome: an umbrella review of meta-analyses from randomized controlled trials. Front Endocrinol. 2026;17:1741509. doi:10.3389/fendo.2026.1741509.
  6. Unfer V, Carlomagno G, Dante G, Facchinetti F. Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. Endocr Connect. 2017;6(8):647–658. doi:10.1530/EC-17-0243. PMC5655679. PMID:29042448.
  7. Benelli E, Del Ghianda S, Di Cosmo C, Tonacchera M. A Combined Therapy with Myo-Inositol and D-Chiro-Inositol Improves Endocrine Parameters and Insulin Resistance in PCOS Young Overweight Women. Int J Endocrinol. 2016;2016:3204083. PMID:27493664.
  8. Nordio M, Basciani S, Camajani E. The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios. Eur Rev Med Pharmacol Sci. 2019;23(12):5512–5521. doi:10.26355/eurrev_201906_18223. PMID:31298405.
  9. Colazingari S, Treglia M, Najjar R, Bevilacqua A. The combined therapy myo-inositol plus d-chiro-inositol, rather than d-chiroinositol, is able to improve IVF outcomes: results from a randomized controlled trial. Arch Gynecol Obstet. 2013;288(6):1405–1411. doi:10.1007/s00404-013-2855-3.
  10. Monastra G, De Grazia S, De Luca L, Vittorio S. May myo-inositol and D-chiro-inositol (40:1) treatment be a good option on normal-weighted PCOS patients without insulin resistance? J Obstet Gynaecol. 2021;41(2):315–319. doi:10.1111/jog.14505.
  11. Facchinetti F, Orrù B, Grandi G, Unfer V. Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): a meta-analysis of randomized clinical trials. Gynecol Endocrinol. 2019;35(3):198–206. doi:10.1080/09513590.2018.1540578. PMID:30614282.
  12. [Authors TBD]. Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and metaanalysis of randomized controlled trials. 2023. PMC9878965.
  13. [Authors TBD]. Inositol supplementation efficacy in improving key cardiometabolic and anthropometric indices: a GRADEassessed systematic review and meta-analysis of randomized controlled trials. Diabetol Metab Syndr. 2025;17:411. doi:10.1186/s13098-025-01980-6.
  14. Giordano D, Corrado F, Santamaria A, et al. Effects of Inositol(s) in Women with PCOS: A Systematic Review of Randomized Controlled Trials. Int J Endocrinol. 2016;2016:1849162. doi:10.1155/2016/1849162.
  15. [Authors TBD]. Comparative efficacy of combined myo-inositol and D-chiro inositol versus metformin across PCOS Phenotypes: enhancing ovarian function, ovulation, and stress response in a prospective clinical trial. Naunyn Schmiedebergs Arch Pharmacol. 2025. PMID:39847053. ClinicalTrials.gov NCT05767515.
  16. Corrado F, D'Anna R, Di Vieste G, et al. The influence of different inositol stereoisomers supplementation in pregnancy on maternal gestational diabetes mellitus and fetal outcomes in high-risk patients: a randomized controlled trial. J Matern Fetal Neonatal Med. 2011;24(2):342–346. PMID:30558466.
  17. Taylor MJ, Wilder H, Bhati B, Geddes JR. A meta-analysis of inositol for depression and anxiety disorders. J Psychopharmacol. 2004;18(3):–. doi:10.1177/0269881113517161. PMID:24424706.
  18. De Rosa A, Fiorentino A, Rossi A, et al. Safety of inositol supplementation in patients taking lithium or valproic acid: a pilot clinical study. Eur Rev Med Pharmacol Sci. 2022;26(20):7269–7276. doi:10.26355/eurrev_202210_29920.
  19. Carlomagno G, Unfer V. Inositol safety: clinical evidences. Eur Rev Med Pharmacol Sci. 2011;15(8):931–936. PMID:21845803.
  20. Myo-Inositol for Infertility in PCOS. ClinicalTrials.gov identifier: NCT04407754. University of Oklahoma. Registered 2020. https://clinicaltrials.gov/study/NCT04407754
  21. U.S. Food and Drug Administration. Code of Federal Regulations, Title 21, Part 184, Section 184.1370 — Inositol. GRAS affirmed. Federal Register 1982. https://www.govregs.com/regulations/title21_chapterIi2_part184_subpartB_section184.1370

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

This article is intended for informational and educational purposes only and does not constitute medical advice. Consult a qualified healthcare professional before beginning supplementation, particularly if pregnant, nursing, taking prescription medications, or managing a diagnosed medical condition.

© 2026 Pacific Formulations. Prepared June 2026.

Tags: 40:1 ratio d-chiro-inositol ingredient research insulin sensitivity myo-inositol ovulation support PCOS white paper
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.